Velcade displays promising activity in primary effusion lymphoma cells.
McConkey
David
D
Department of Cancer Biology, Univesity of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA. dmcconke@mdanderson.org
Nawrocki
Steffan T
ST
Andtbacka
Robert
R
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects*; D001897:Boronic Acids / Q000494:pharmacology* / Q000627:therapeutic use; D000069286:Bortezomib; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D016066:Pleural Effusion, Malignant / Q000473:pathology*; D011719:Pyrazines / Q000494:pharmacology* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib